

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Qyuns Therapeutics Co., Ltd.
江蘇荃信生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2509)

**SUPPLEMENTAL ANNOUNCEMENT
IN RELATION TO THE ANNUAL REPORT
FOR THE YEAR ENDED DECEMBER 31, 2024**

Reference is made to the annual report of Qyuns Therapeutics Co., Ltd. (“**Company**”, together with its subsidiaries, the “**Group**”) for the year ended December 31, 2024 (“**Annual Report**”) published on April 29, 2025. Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Annual Report.

The Board would like to provide the following information (with supplemental information underlined) regarding the emoluments paid or payable to the directors and the chief executive of the Company for the year ended 31 December 2024 in addition to the information provided in the 2024 Annual Report. Save as disclosed herein, all other information in the Annual Report remains unchanged.

Details of the emoluments of the directors and supervisors of the Company for the year ended 31 December 2024 are as follows:

	Salaries, allowances and benefits	Discretionary bonuses	Retirement scheme contributions	Sub-total	Share-based payments	2024 Total
<u>Directors' fees</u>	<u>in kind</u>	<u>bonuses</u>	<u>contributions</u>	<u>Sub-total</u>	<u>payments</u>	<u>2024 Total</u>
<u>RMB'000</u>	<u>RMB'000</u>	<u>RMB'000</u>	<u>RMB'000</u>	<u>RMB'000</u>	<u>RMB'000</u>	<u>RMB'000</u>
Executive directors						
Mr. Qiu Jiwan (裘霽宛)(i)	=	1,864	720	45	2,629	39,581
Mr. Wu Yiliang (吳亦亮)(ii)	=	1,084	300	45	1,429	4,523
Mr. Lin Weidong (林偉棟)(viii)	=	1,273	400	71	1,744	6,267
Non-executive directors						
Mr. Yu Xi (余熹)(iii)	=	-	-	-	-	-
Dr. Xue Mingyu (薛明宇)(iv)	=	-	-	-	-	-
Mr. Wu Zhiqiang (吳志強)(v)	=	-	-	-	-	-

	Directors' fees	Salaries, allowances and benefits in kind	Discretionary bonuses	Retirement scheme contributions	Sub-total	Share-based payments	2024 Total
	<u>RMB'000</u>	<u>RMB'000</u>	<u>RMB'000</u>	<u>RMB'000</u>	<u>RMB'000</u>	<u>RMB'000</u>	<u>RMB'000</u>
Supervisors							
Ms. Wang Yujiao (王玉姣)(vi)	=	604	160	45	809	2,505	3,314
Mr. Ye Xiang (葉翔)(vii)	=	-	-	-	-	-	-
Dr. Ding Chao (丁超)(ix)	=	-	-	-	-	-	-
	=	4,825	1,580	206	6,611	47,074	53,685
Independent Non-executive Directors							
Dr. Zou Zhongmei (鄒忠梅)(xi)	185	=	=	=	185	=	185
Dr. Ling Jianqun (凌建群)(xi)	185	=	=	=	185	=	185
Mr. Fung Che Wai, Anthony (馮志偉)(xi)	185	=	=	=	185	=	185
	<u>555</u>	<u>4,825</u>	<u>1,580</u>	<u>206</u>	<u>7,166</u>	<u>47,074</u>	<u>54,240</u>

Notes:

- (i) Mr. Qiu Jiwan (裘霽宛) was appointed as an executive director of the Company on 16 June 2015. He was key management personnel of the Group and his remuneration disclosed above included those for services rendered by him as key management personnel.
- (ii) Mr. Wu Yiliang (吳亦亮) was appointed as an executive director of the Company on 10 April 2019. He was key management personnel of the Group and his remuneration disclosed above included those for services rendered by him as key management personnel.
- (iii) Mr. Yu Xi (余熹) was appointed as a non-executive director of the Company on 14 August 2020.
- (iv) Dr. Xue Mingyu (薛明宇) was appointed as a non-executive director of the Company on 29 March 2021 and resigned on 10 December 2024 due to personal commitments.
- (v) Mr. Wu Zhiqiang (吳志強) was appointed as a non-executive director of the Company on 17 September, 2021.
- (vi) Ms. Wang Yujiao (王玉姣) was appointed as a supervisor of the Company on 17 September 2021. She was also an employee of the Group and the Group paid emoluments to her in her capacity as the employee of the Group before her appointment as a supervisor of the Company.
- (vii) Mr. Ye Xiang (葉翔) was appointed as a supervisor of the Company on 17 September 2021.
- (viii) Mr. Lin Weidong (林偉棟) was appointed as an executive director of the Company on 16 March 2022. He was key management personnel of the Group and his remuneration disclosed above included those for services rendered by him as key management personnel.
- (ix) Dr. Ding Chao (丁超) was appointed as a supervisor of the Company on 15 September 2022.

- (x) During the year ended 31 December 2024, there was no amounts paid or payable by the Group to the directors as an inducement to join or upon joining the Group or as a compensation for loss of office.
- (xi) Dr. Zou Zhongmei (鄒忠梅), Dr. Ling Jianqun (凌建群) and Mr. Fung Che Wai, Anthony (馮志偉), were appointed as our independent non-executive Directors on January 4, 2024. As no independent non-executive directors were appointed prior to 31 December 2023, there were no emoluments for independent non-executive directors for the year ended December 31, 2023.

The independent non-executive directors were not entitled to any salaries, allowances and benefits in kind, discretionary bonus, retirement scheme contributions and share-based payments for the financial year ended December 31, 2024.

By Order of the Board
Qyuns Therapeutics Co., Ltd.
Mr. Qiu Jiwan

Chairman of the Board and Executive Director

Hong Kong, June 30, 2025

As at the date of this announcement, the Board comprises Mr. Qiu Jiwan as chairman and executive Director, Mr. Wu Yiliang and Mr. Lin Weidong as executive Directors, Mr. Yu Xi and Mr. Wu Zhiqiang as non-executive Directors, and Dr. Zou Zhongmei, Dr. Ling Jianqun and Mr. Fung Che Wai, Anthony as independent non-executive Directors.